Aducanumab Data Finally Published, but Alzheimer’s Experts Spot Problems
The long-awaited results of the twin phase III trials for aducanumab (Aduhelm), the controversial drug approved last year for early Alzheimer’s disease, were published in the Journal of Prevention of Alzheimer’s Disease (JPAD), a journal whose editor-in-chief is aducanumab researcher and study co-author Paul Aisen, MD, of the University of Southern California in Los Angeles. […]